
|Articles|December 3, 2012
FDA approves cabozantinib to treat rare type of thyroid cancer
FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Executive Order Calls for Realignment of Childhood Vaccines
2
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
3
Q&A: Pharmacists Can Address ADA Standards Across All Settings
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































